

bs-16924R**[Primary Antibody]****KCTD1 Rabbit pAb****Bioss**
ANTIBODIES

www.bioss.com.cn


sales@bioss.com.cn

techsupport@bioss.com.cn

400-901-9800

— DATASHEET —

| | | |
|--|----------------------|--|
| Host: Rabbit | Isotype: IgG | Applications: WB (1:500-2000) |
| Clonality: Polyclonal | | Reactivity: Mouse (predicted: Human, Rat, Rabbit) |
| GeneID: 284252 | SWISS: Q719H9 | |
| Target: KCTD1 | | Predicted MW.: 29 kDa |
| Immunogen: KLH conjugated synthetic peptide derived from human KCTD1: 201-257/257. | | Subcellular Location: Nucleus |
| Purification: affinity purified by Protein A | | |
| Concentration: 1mg/ml | | |
| Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. | | |
| Background: KCTD1 (potassium channel tetramerisation domain containing 1), also known as C18orf5, is a 257 amino acid protein that contains one BTB domain, suggesting an involvement in transcriptional control. The gene encoding KCTD1 maps to human chromosome 18, which houses over 300 protein-coding genes and contains nearly 76 million bases. There are a variety of diseases associated with defects in chromosome 18-localized genes, some of which include Trisomy 18 (also known as Edwards syndrome), Niemann-Pick disease, hereditary hemorrhagic telangiectasia, erythropoietic protoporphyria and follicular lymphomas. | | |

— VALIDATION IMAGES —

Sample: Lane 1: Mouse Cerebrum tissue lysates

Lane 2: Mouse Kidney tissue lysates Primary:

Anti-KCTD1 (bs-16924R) at 1/1000 dilution

Secondary: IRDye800CW Goat Anti-Rabbit IgG at

1/20000 dilution Predicted band size: 29 kDa

Observed band size: 33 kDa

— SELECTED CITATIONS —

- **[IF=5.3]** Escudero-Cernuda Sara. et al. Limitations and challenges in the characterization of extracellular vesicles from stem cells and serum. MICROCHIM ACTA. 2025 May;192(5):1-12 FC ;Human. 40259021
- **[IF=4.9]** Zhu Xinyu. et al. Exosomes delivering miR-129-5p combined with sorafenib ameliorate hepatocellular carcinoma progression via the KCTD1/HIF-1 α /VEGF pathway. CELL ONCOL. 2025 Apr;1-18 IHC ;Human. 40227531